Expertise in
35
conditions

Wilma Barcellini

Milan, IT 
Expertise in
35
conditions
Milan, IT 

Overview

Wilma Barcellini practices in Milan, Italy. Ms. Barcellini is highly rated in 35 conditions, according to our data. Her top areas of expertise are Autoimmune Hemolytic Anemia, Hemolytic Anemia, Anemia, Splenectomy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 243 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Milan, Italy
Other Locations
Ca' Granda, Italy
Via F. Sforza 35 20122 Milan, Via, 20122, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia
A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Isatuximab SAR650984, Diphenhydramine, Famotidine, Acetaminophen, Montelukast
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Enrollment Status: Completed
Publish Date: August 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.
Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.
Enrollment Status: Completed
Publish Date: October 14, 2020
Pyruvate Kinase Deficiency (PKD) Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Enrollment Status: Completed
Publish Date: May 22, 2020
View 6 Less Clinical Trials

243 Total Publications

Management of autoimmune hemolytic anemia.
Management of autoimmune hemolytic anemia.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Frequently Asked Questions about Wilma Barcellini

Is Wilma Barcellini a top-rated expert for Autoimmune Hemolytic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Wilma Barcellini is classified as an Elite expert for Autoimmune Hemolytic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wilma Barcellini participate in research or clinical trials?

Yes. Wilma Barcellini has published 243 articles and abstracts on conditions like Autoimmune Hemolytic Anemia. You can view a list of Wilma Barcellini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Barcellini's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 12 Advanced Conditions
View All 51 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile